Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 22, 2022ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Open Access

Lixisenatide drives ~6% greater BNP reduction vs placebo in T2D with recent ACS.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does lixisenatide improve natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome?

Population

People with type 2 diabetes and recent acute coronary syndrome

Key result

Lixisenatide resulted in a 6.1% greater reduction in BNP and a 7.1% greater reduction in NT-proBNP compared to placebo in patients with type 2 diabetes and recent acute coronary syndrome.

Authors

HGHertzel C. GersteinEWEmil WolskBCBrian Claggett

Discussion

Loading...

Member takes

Overview

May lower natriuretic peptides post-ACS; hypothesis-generating and should not yet change practice.

Study Design

Type

RCT (n=5,551)

Blinding

Double-blind

Randomization

Randomly assigned

Multicenter

Yes

Structured PICO

Does lixisenatide improve natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome?

P
Population
5,551 middle-aged and older adults with type 2 diabetes and a recent acute coronary syndrome, followed for a median of 29 months.
I
Intervention
Lixisenatide
O
Outcome
Natriuretic peptidessurrogate

Main Result

Mean Difference: 6.1 (95% CI 2.7–9.4)

Absolute Event Rate: 23.4% vs 18.4%

p-value: p=<0.001

Limitations

  • Absence of other mechanistic studies
  • Absence of functional measurements of cardiac function

Cite This Study

Gerstein et al. (2022) conducted an RCT in Type 2 diabetes and recent acute coronary syndrome (n=5,551). Lixisenatide vs. Matching placebo was evaluated on Percent change from baseline in B-type natriuretic peptide (BNP) (MD 6.1%, 95% CI 2.7-9.4, p=<0.001). Lixisenatide resulted in a 6.1% greater reduction in BNP and a 7.1% greater reduction in NT-proBNP compared to placebo in patients with type 2 diabetes and recent acute coronary syndrome.

synapsesocial.com/papers/6aa79a0c3aaa4d3bb544b456https://doi.org/10.1111/dom.14954
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 11896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 582024 · 3 citations
  2. 2Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial2025 · 2 citations
  3. 31247-OR: Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial2026
  4. 42202-P: The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist in a Trial Inspired, and Wider, Population Individuals Living with Type 2 Diabetes: A Target Trial Emulation Study in CPRD2026
  5. 51217-OR: ApoC3 Inhibitor Olezarsen Markedly Reduces Triglycerides and Risk of Pancreatitis in Severe Hypertriglyceridemia Patients with Diabetes Mellitus: Insights from CORE-TIMI 72a and CORE2-TIMI 72b2026